170 related articles for article (PubMed ID: 10845726)
1. Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system.
Rubinchik S; Ding R; Qiu AJ; Zhang F; Dong J
Gene Ther; 2000 May; 7(10):875-85. PubMed ID: 10845726
[TBL] [Abstract][Full Text] [Related]
2. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression.
Rubinchik S; Wang D; Yu H; Fan F; Luo M; Norris JS; Dong JY
Mol Ther; 2001 Nov; 4(5):416-26. PubMed ID: 11708878
[TBL] [Abstract][Full Text] [Related]
3. New complex Ad vectors incorporating both rtTA and tTS deliver tightly regulated transgene expression both in vitro and in vivo.
Rubinchik S; Woraratanadharm J; Yu H; Dong JY
Gene Ther; 2005 Mar; 12(6):504-11. PubMed ID: 15660114
[TBL] [Abstract][Full Text] [Related]
4. Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector.
Rubinchik S; Yu H; Woraratanadharm J; Voelkel-Johnson C; Norris JS; Dong JY
Cancer Gene Ther; 2003 Nov; 10(11):814-22. PubMed ID: 14605667
[TBL] [Abstract][Full Text] [Related]
5. A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo.
Gu J; Zhang L; Huang X; Lin T; Yin M; Xu K; Ji L; Roth JA; Fang B
Oncogene; 2002 Jul; 21(31):4757-64. PubMed ID: 12101414
[TBL] [Abstract][Full Text] [Related]
6. Autocrine and paracrine apoptosis are mediated by differential regulation of Fas ligand activity in two distinct Jurkat T cell populations.
Su X; Cheng J; Liu W; Liu C; Wang Z; Yang P; Zhou T; Mountz JD
J Immunol; 1998 Jun; 160(11):5288-93. PubMed ID: 9605126
[TBL] [Abstract][Full Text] [Related]
7. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
[TBL] [Abstract][Full Text] [Related]
8. Regulation of transgene expression using an inducible system for improved safety of intervertebral disc gene therapy.
Vadalà G; Sowa GA; Smith L; Hubert MG; Levicoff EA; Denaro V; Gilbertson LG; Kang JD
Spine (Phila Pa 1976); 2007 Jun; 32(13):1381-7. PubMed ID: 17545904
[TBL] [Abstract][Full Text] [Related]
9. FasL gene therapy: a new therapeutic modality for head and neck cancer.
ElOjeimy S; McKillop JC; El-Zawahry AM; Holman DH; Liu X; Schwartz DA; Day TA; Dong JY; Norris JS
Cancer Gene Ther; 2006 Aug; 13(8):739-45. PubMed ID: 16543918
[TBL] [Abstract][Full Text] [Related]
10. Recombinant AAV-mediated delivery of a tet-inducible reporter gene to the rat retina.
McGee Sanftner LH; Rendahl KG; Quiroz D; Coyne M; Ladner M; Manning WC; Flannery JG
Mol Ther; 2001 May; 3(5 Pt 1):688-96. PubMed ID: 11356074
[TBL] [Abstract][Full Text] [Related]
11. Lentiviral vectors: regulated gene expression.
Kafri T; van Praag H; Gage FH; Verma IM
Mol Ther; 2000 Jun; 1(6):516-21. PubMed ID: 10933976
[TBL] [Abstract][Full Text] [Related]
12. FasL induces Fas/Apo1-mediated apoptosis in human embryonic kidney 293 cells routinely used to generate E1-deleted adenoviral vectors.
Larregina AT; Morelli AE; Dewey RA; Castro MG; Fontana A; Lowenstein PR
Gene Ther; 1998 Apr; 5(4):563-8. PubMed ID: 9614583
[TBL] [Abstract][Full Text] [Related]
13. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells.
Sun SY; Yue P; Hong WK; Lotan R
Cancer Res; 2000 Nov; 60(22):6537-43. PubMed ID: 11103825
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
Lowe SL; Rubinchik S; Honda T; McDonnell TJ; Dong JY; Norris JS
Gene Ther; 2001 Sep; 8(18):1363-71. PubMed ID: 11571575
[TBL] [Abstract][Full Text] [Related]
15. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis.
Huerta-Yepez S; Vega M; Garban H; Bonavida B
Clin Immunol; 2006 Sep; 120(3):297-309. PubMed ID: 16784892
[TBL] [Abstract][Full Text] [Related]
16. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes.
Lin T; Gu J; Zhang L; Huang X; Stephens LC; Curley SA; Fang B
Cancer Res; 2002 Jul; 62(13):3620-5. PubMed ID: 12097263
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells.
Hedlund TE; Meech SJ; Srikanth S; Kraft AS; Miller GJ; Schaack JB; Duke RC
Cell Death Differ; 1999 Feb; 6(2):175-82. PubMed ID: 10200564
[TBL] [Abstract][Full Text] [Related]
18. Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression.
Hyer ML; Sudarshan S; Schwartz DA; Hannun Y; Dong JY; Norris JS
Cancer Gene Ther; 2003 Apr; 10(4):330-9. PubMed ID: 12679806
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.
Kagawa S; He C; Gu J; Koch P; Rha SJ; Roth JA; Curley SA; Stephens LC; Fang B
Cancer Res; 2001 Apr; 61(8):3330-8. PubMed ID: 11309289
[TBL] [Abstract][Full Text] [Related]
20. Tetracycline-inducible transgene expression mediated by a single AAV vector.
Chtarto A; Bender HU; Hanemann CO; Kemp T; Lehtonen E; Levivier M; Brotchi J; Velu T; Tenenbaum L
Gene Ther; 2003 Jan; 10(1):84-94. PubMed ID: 12525840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
